Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Sanofi wants to broaden the company s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.